Clinical trial
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the…
NCT00074542 · Tillotts Pharma AG, Industry · Completed
Key facts
| NCT number | NCT00074542 |
|---|---|
| Title | An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease |
| Official title | A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease |
| Lead sponsor | Tillotts Pharma AG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Epanova™ (Omega-3 Free Fatty Acids) |
| Enrollment | 364 |
| Start date | Sep 1, 2002 |
| Completion | Jan 1, 2005 |
| First posted | Dec 16, 2003 |
| Last update posted | Feb 21, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: